Rob Finch

Director, Urology Medical Affairs, Certified Genetic Counselor at Myriad Genetic Laboratories | Lover of everything Broadway (he/him/his)

[Matt Cooperberg @dr_coops]

Prolaris is teaming up with PathomIQ for a genomic-pathAI joint initiative which is pretty exciting; in the meantime, useful meta-analysis of results to date over the years @myriadgenetics #GU26

[Myriad Genetics @myriadgenetics]

We’re excited to share data from seven studies at the upcoming 2024 @ASCO Annual Meeting. Three studies led by Myriad focus on breast cancer risk assessment, and four additional studies will be shared by collaborators that will cover the our Precise™ MRD Test, MyChoice® CDx HRD Companion Diagnostic Test, and the Myriad Collaborative Research Registry™.

Read the press release: https://t.co/LPNJ8Hc6T2

[Rob Finch @RobFinchCGC]

I grew up in the arts and have always felt like science and art complement one another. I’m particularly passionate when medicine and art collide. I love that we’ll get to see the pre-Broadway run of @DeathBecomesBwy while attending #ASCO2024 @myriadgenetics @ProlarisTest

[Rob Finch @RobFinchCGC]

Heading to Chicago for this year’s @ASCO Annual Meeting. Happy to meet with anyone who has questions about the genetics and genomics of #ProstateCancer and how to incorporate testing into your practice. @ProlarisTest @MyriadMyRisk
#PreciseTumor @myriadgenetics #ASCO2024

[Urology Times @UrologyTimes]

Recently published data indicate that the Prolaris Test can accurately predict which patients may benefit from adding ADT to radiation therapy for prostate cancer. #pcsm #urology @prostatemd @huntsmancancer
@Huntsman_GU
https://t.co/iTbAnEG6i2

[Myriad Genetics @myriadgenetics]

Today we announced that JCO Precision Oncology has published a study showing a clinical cell-cycle risk (CCR) score can accurately predict the benefit of adding androgen deprivation therapy (ADT) to radiation therapy (RT) in men with localized prostate cancer.

Read the press release: https://t.co/oYwmnj8c7l

[Rob Finch @RobFinchCGC]

At @ASCO #GU24? Come by the poster session, Board P5 to see our poster “Safety and clinical validity of tumor genomic testing for guiding active surveillance selection in men with NCCN intermediate risk prostate cancer” @ProlarisTest @myriadgenetics

[Lauren Giannetti Sferrazza MS, LGC @LGtheCGC]

When the waiter wants to join in on the @myriadgenetics fun!! @ShellyCumming18 @natascha_saylor @RobFinchCGC #NSGC23

[Myriad Genetics @myriadgenetics]

Today at #NSGC23: Join us for a CEU Lunch Symposium - Patients, Partnership, and Purpose: A Panel Discussion​, 12:45-2pm.

#Cancer and #prenatal patients share their experience with #genetictesting and screening alongside genetic counselors and scientists, discussing the clinical details and the technology that made it possible. #GeneChat

Learn more: https://t.co/LRVPeQmuCQ

[Rob Finch @RobFinchCGC]

Drop by the Myriad booth at the NSGC Annual Education Conference to update your headshot! You’re bound to get some good networking opportunities in this line! Booth #317 @myriadgenetics @MyriadMyRisk #NSGC23

[Myriad Genetics @myriadgenetics]

If you are attending #NSGC23, visit the Myriad Genetics booth #317 and learn how genetic insights can help to improve the health and well-being of patients. Learn more: https://t.co/yFzmJaNDNV #GeneChat

[Myriad Genetics @myriadgenetics]

Will you be in Chicago for #NSGC23? Join us on October 20 from 7 p.m. to 10 p.m. at the John Hancock Building for our 10th Annual Genetic Counselor Appreciation Night and Fundraiser!

We're looking forward to a fun night of:

📣 Good conversation
🎵 Music
🍕 Food
💫 Taking a spin on the 360 Chicago TILT Tide (ideally not too soon after enjoying the food....)

Learn more: https://t.co/v3hfq0voPL

#GeneChat #Chicago

[Rob Finch @RobFinchCGC]

Attending #ASTRO2023? Come by our booth to learn how Prolaris can help with ADT decision-making. Myriad Genetics. Booth 3614 @ProlarisTest @myriadgenetics

[Rob Finch @RobFinchCGC]

Check out our poster “Active Surveillance Selection and Durability in Men with NCCN Intermediate Risk, Localized Prostate Cancer Who Had Genetic Testing” being presented at #WSAUA23. @ProlarisTest @myriadgenetics

[Myriad Genetics @myriadgenetics]

Explore the cutting-edge enhancement to the Prolaris test and its impact on precision medicine. Don't miss this opportunity to learn from leading experts in the field and stay at the forefront of advancements in #prostatecancer care. Register today! https://t.co/wbU3bP3RNI

[Myriad Genetics @myriadgenetics]

Thanks to everyone who stopped by Dr. Tward’s poster presentation on “Predicting Absolute Benefit in Risk of Metastasis of #ADT added to Radiation Therapy in Patients with Newly Diagnosed #ProstateCancer” @RobFinchCGC #ASCO23

[Rob Finch @RobFinchCGC]

Join us at this morning’s poster session at #ASCO23. Come by Board 124 to discuss with Dr Tward “Predicting Absolute Benefit in Risk of Metastasis of ADT added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer” @ProlarisTest @myriadgenetics

[Myriad Genetics @myriadgenetics]

To help raise awareness and educate men on the various aspects of the #ProstateCancer journey, we’ve created a free eBook to provide valuable information from time of diagnosis to treatment options to patient resources and much more. View eBook https://t.co/TYm3rOwA7q